|
A phase I clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of FN-1501 monotherapy in patients with advanced solid tumors. |
|
|
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CBT Pharmaceuticals (Inst); Corvus Pharmaceuticals (Inst); Five Prime Therapeutics (Inst); Fosun Pharma (Inst); Merck (Inst); Novotech (Inst); Pfizer (Inst); Roche/Genentech (Inst); Shanghai Henlius Biotech (Inst); Suzhou Alphamab (Inst); Takeda (Inst) |
|
|
Honoraria - Bayer; Bristol-Myers Squibb; Exelixis; Genentech; Janssen; Novartis; Pfizer; Sanofi |
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Pfizer |
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Pfizer; Sanofi |
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Novartis; Pfizer |
|
|
Employment - Fosun Pharma |
|
|
No Relationships to Disclose |
|
|
Employment - Fosun Pharma |
Leadership - Fosun Pharma |
|
|
Research Funding - Acceleron Pharma (Inst); Aleon Pharma (Inst); Astellas Pharma (Inst); Bayer Health (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Merck Serono (Inst); Nektar (Inst); Novartis (Inst); Pharmacyclics (Inst); Regeneron (Inst); Rogosin Institute (Inst); Sanofi (Inst); Seagen (Inst); Sotio (Inst) |